BPC-157 + TB-500
The recovery pairing often called the Wolverine stack.
The short version
Ingredients
- Why people discuss it
- Discussed for soft-tissue recovery. The Wolverine nickname describes the community’s hoped-for effect; it is not evidence of faster healing.
- What it is
- A pairing of BPC-157 and a product called TB-500, supplied separately or as a blend. Verify the actual substance and ingredient amounts; TB-500 and full-length thymosin beta-4 are not automatically interchangeable.
- Biggest caution
- A small uncontrolled knee report included BPC-157 plus TB4. It did not establish added benefit, general safety, or equivalence to a community TB-500 product.
- Stack context
- This pair is the ingredient base of GLOW and KLOW. Those names add ingredients, not proof that the combinations work better.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Source agreement describes reported practice, not clinical validation.
BPC-157 + TB-500 — separate subcutaneous products
Community reference · Not clinical guidance- Amount
- BPC-157 100–250 mcg; TB-500 1–1.5 mg per administration
- Frequency
- BPC-157 daily; TB-500 twice weekly during loading
- Duration / phase
- Reported recovery course: 4–8 weeks
Peptidepedia’s separate-product example, not a premixed-vial dose. Its TB-500 discussion uses a 4–6-week loading phase. PeptideDosages supplies a different 12-week example. Neither establishes combination benefit or safety. Reference only; this does not establish safety, effectiveness or individual suitability.
Community source · reviewed 2026-09-27Compare reported schedules
Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.
- PeptideDosages — saved source reviewed September 27, 2026
Separate-vial example BPC 250–500 mcg daily plus TB 1.25 mg twice/week then weekly, 12-week table. Premixed 1:1 daily examples differ.
- Peptidepedia — saved source reviewed September 27, 2026
BPC 100–250 mcg daily plus TB 1–1.5 mg twice/week during loading, 4–8-week recovery course.
Evidence & sources · Combination evidence limited
Community references document claims and reported practices. They are not clinical evidence. Some references contain supplier promotions or market treatment; their commercial context is identified in the source label.
- Plastic Surgery Key: Wolverine, GLOW and KLOW naming (supplier-promotional article)Community reference · Checked 2026-09-12
- BPC-157 plus TB4 subgroup in the knee reportExisting research · Checked 2026-09-08
- FDA: peptide compounding safety concernsRegulatory source · Checked 2026-09-12
- PeptideDosages — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27
- Peptidepedia — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27